β受体阻滞剂自20世纪60年代以来已广泛用于治疗高血压、冠心病、心力衰竭、心律失常、心肌病等。1978年世界卫生组织正式将β受体阻滞剂列为高血压治疗的一线药物,以后各国高血压防治指南均将β受体阻滞剂列为降压一线药物或主要药物。2005年,Lindholm在一项β受体阻滞剂阿替洛尔治疗高血压的临床研究中发现,β受体阻滞剂组患者发生脑卒中的相对危险较其他降压药组高 Beta blockers since the 1960s has been widely used in the treatment of hypertension, coronary heart disease, heart failure, arrhythmia, cardiomyopathy and so on. In 1978, the WHO formally listed beta-blockers as the first-line drug for the treatment of hypertension. Afterwards, the guidelines for the prevention and treatment of hypertension in all countries included beta-blockers as the first-line drugs or major drugs for lowering blood pressure. In 2005, Lindholm found that the relative risk of stroke in beta-blocker group was higher than that of other antihypertensive drugs in a clinical study of atenolol, a beta blocker,